Skip to content

Taurine as a Possible Anti-aging Therapy?

Taurine as a Possible Anti-aging Therapy? A Controlled Clinical Trial on Taurine Antioxidant Activity in Women Aged 55 to 70 Years

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05149716
Enrollment
24
Registered
2021-12-08
Start date
2020-01-13
Completion date
2020-07-03
Last updated
2021-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oxidative Stress

Keywords

Aging, Oxidative Stress, Taurine, Nutritional Supplementation, Therapeutic Strategy

Brief summary

Among the strategies that can improve the body's ability to counteract oxidative stress, the use of nutritional antioxidants has been investigated. Taurine is a semi-essential amino acid, also called a nitrogen compound, which has been used as an effective antioxidant due to its ability to neutralize hypochlorous acid, an extremely toxic oxidant produced by leukocytes in the inflammatory process in humans.

Detailed description

Objective: To evaluate the oxidative parameters of women aged 55 to 70 years after 16 weeks of taurine supplementation. Methods: Twenty-four women age 55 to 70 will be randomly assigned to two groups: control group (GC), supplemented with placebo (1.5 g of starch); and taurine group (GTAU), supplemented with taurine (1.5 g), for 16 weeks. Anthropometry, functional capacity test, taurine, and levels of oxidative stress markers will be determined in pre and post intervention plasma samples. Food consumption will be assessed before, during, and after the intervention. The results will be analyzed by an ANOVA two-way repeated measures mixed model, with the Sidak post hoc (p \< 0.05).

Interventions

DIETARY_SUPPLEMENTTaurine

Taurine supplementation in capsules of 500 grams of taurine powder, total dosage: 1.5 gram/day

DIETARY_SUPPLEMENTPlacebo

Placebo supplementation in capsules of 500 grams of starch powder, total dosage: 1.5 gram/day

Sponsors

Fundação de Amparo à Pesquisa do Estado de São Paulo
CollaboratorOTHER_GOV
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.
CollaboratorOTHER_GOV
University of Sao Paulo
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Masking description

Supplement capsule packages were labeled as Supplement A and Supplement B and the nutrient (taurine or placebo- starch) was revealed after the end of the intervention.

Intervention model description

Double-blind placebo controlled study

Eligibility

Sex/Gender
FEMALE
Age
55 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* Had being aged 55-70 years; * Female; * Post-menopausal; * Sedentary (not practicing physical exercise for at least 6 months).

Exclusion criteria

* Chronic kidney diseases; * Infectious contagious diseases; * Coronary heart disease; * Smokers * Alcoholics.

Design outcomes

Primary

MeasureTime frameDescription
Change from baseline in blood oxidative stress marker measurement - Superoxide Dismutase (SOD).sixteen weeksThe superoxide dismutase (SOD) activity in erythrocytes was evaluated by the spectrophotometric method, and were calculated at 16 weeks in comparision to the baseline.
Change from baseline in blood oxidative stress marker measurement - Glutathione reductase (GR).sixteen weeksGlutathione reductase (GR) activity was determined by the spectrophotometric method at 37 ºC/340nm after the oxidation of NADPH in the presence of oxidized glutathione, and were calculated at 16 weeks in comparision to the baseline.
Change from baseline in blood oxidative stress marker measurement - Malondialdehyde (MDA).sixteen weeksThe malondialdehyde (MDA) were calculated at 16 weeks in comparision to the baseline.

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026